ARNA Panacea Project Overview
ARNA Panacea is an innovative biotechnology decentralized solution, with the core goal of applying blockchain technology to the management of clinical trial data and the distribution of biotechnology products. The project was officially launched on September 14, 2017, aiming to address pain points in data transparency, security, and efficiency in traditional healthcare and clinical research fields.
Core Functions and Technical Architecture
The ARNA Panacea platform is dedicated to building an efficient marketplace for all market participants in clinical trials, including researchers, investors, patients, regulatory bodies (such as the FDA), contract research organizations (CROs), insurance companies, pharmaceutical companies, and clinics. It provides a decentralized framework that supports researchers during the R&D phase and facilitates the direct sale of biotechnology end-products to patients.
At the technical level, ARNA Panacea employs a customized permissioned blockchain, a design considered more suitable for the healthcare sector because it can handle critical timestamp registration information and more easily comply with stringent regulatory requirements. Furthermore, to further enhance data immutability, the project utilizes blockchain anchoring technology to periodically submit block header hashes to the Bitcoin public blockchain.
ARNA Token and Ecosystem
The ARNA Panacea platform is powered by its native token, ARNA, an ERC20 standard token based on the Ethereum blockchain. The ARNA token plays a crucial role in the ecosystem, potentially used for platform service fees, incentivizing participants, or as part of a governance mechanism. However, key data such as the maximum supply, total supply, and circulating supply of ARNA tokens are marked as "not applicable" or undisclosed in public records, indicating limited market activity or public trading information. As of the time of writing, the ARNA token's all-time high price reached $0.05, with its current price around $0.004892, but due to the lack of reliable supply data, its market capitalization and liquidity are difficult to accurately assess. Investors considering such tokens must fully understand the potential risks and can verify the latest prices and project information on news platforms like Svmuu.
ARNA Genomics Association and Historical Progress
ARNA Genomics is considered the entity behind the ARNA Panacea project and its biotechnology solutions. The company has made some notable progress in the biotechnology field:
- In September 2020, ARNA Genomics raised $3.5 million in Series A funding for its ARNA Breast Cancer Detection System.
- In September 2019, its "ARNA Breast" early breast cancer detection showed impressive clinical efficacy in a proof-of-concept study.
- In the same year, ARNA Genomics also won first place in startup competitions such as BIOTECHMED-2019 and "StartUp: Land HealthNet."
These historical events indicate ARNA Genomics' strength in biotechnology R&D, but its specific linkage with the ARNA Panacea tokenization project and the latest developments require continuous attention to official channel updates.
Availability
Given the lack of key data such as the circulating supply of ARNA tokens in public records, and the inability to verify its trading market activity, there are currently no reliable active trading channels for this token.
